• Recruiting

NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma

Updated: May 26


CC-93269

Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma


Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.


Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma


Sponsor

Celgene

 

ClinicalTrials.gov Identifier: NCT03486067


Official Title: A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.


First Posted : April 3, 2018

 

CC-93269

anti-BCMA/CD3 bispecific antibody CC-93269

BCMA x CD3 T Cell-engaging antibody CC-93269

BCMA/CD3 T-cell bi-specific antibody CC-93269

BCMA/CD3-directed bispecific T-cell engager antibody CC-93269

BCMAxCD3 BiTE antibody CC-93269

BCMAxCD3 TCB CC-93269

bi-specific antibody CC-93269

 

Drug: CC-93269

anti-BCMA/CD3 bispecific antibody CC-93269

 

- Alabama: University of Alabama at Birmingham

- California: University of California San Francisco

- Connecticut: Yale University New Haven

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Massachusetts: Massachusetts General Hospital Boston

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Washington: Swedish Cancer Inst Seattle

 

Locations

United States, Alabama

United States, California

United States, Connecticut

United States, Georgia

United States, Massachusetts

United States, Michigan

United States, New York

United States, Washington

Europe

Germany

Italy

Spain

Sweden










Posts Archive